Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMCISION neoadjuvant nivolumab with or without ipilimumab in resectable advanced or recurrent head and neck squamous cell carcinoma
NL-OMON42832Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Feasibility and safety with respect to surgery timing, Pathological tumor response and 1 more. Started Feb 2017; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON42832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42832.